SA PRO
Free Account
Enhabit, Inc.EHABNYSE
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
10 analysts·Moderate coverage
50%
Rating Distribution
Strong Buy
00%
Buy
550%
Hold
440%
Sell
110%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 22, 2026Oppenheimer
Enhabit upgraded to Outperform from Perform at Oppenheimer
Target:$14.00
+30.4%from $10.74
Jan 8, 2026Wolfe Research
UBS Upgrades Enhabit Home Health & Hospice (EHAB) to Buy
Target:$12.00
+26.2%from $9.51
Jan 7, 2026Truist Financial
Enhabit initiated with a Hold at Truist
Target:$10.50
+11.2%from $9.44
Dec 16, 2025Jefferies
Enhabit price target raised to $12 from $11 at Jefferies
Target:$12.00
+23.4%from $9.72
Dec 9, 2024Jefferies
Jefferies Upgrades Enhabit Home Health & Hospice (EHAB) to Buy
Target:$9.50
+22.9%from $7.73
May 14, 2024Leerink Partners
Enhabit upgraded to Market Perform from Underperform at Leerink
Target:$8.50
-1.6%from $8.64
Dec 8, 2022UBS
UBS Initiates Coverage On Enhabit with Sell Rating, Announces Price Target of $12
Target:$12.00
-14.2%from $13.99

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance